Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Identification of [14C]HRS-8080 in Healthy Chinese Postmenopausal Females
NCT07320521Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-8080 in breast cancer, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Cumulative amount of HRS-8080 excreted, Percentage of parent drug and its metabolite(s) relative to total radioactive exposure in plasma and 9 more. Started Jan 2026; status: completed.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07320521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07320521.